Abrocitinib (Cibinqo®) HTA ID: 21056
Abrocitinib (Cibinqo®) is indicated for the treatment of moderate-to-severe atopic dermatitis in adults aged 18 years and older who are candidates for systemic therapy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 16/11/2021 |
| Rapid review completed | 23/12/2021 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that abrocitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.